issued
on 02 Jan 2024
Last Applicant/ Owned by
430 E. 29th Street, 14th Floor
New York
NY
10016
Serial Number
97060574 filed on 05th Oct 2021
Registration Number
N/A
Correspondent Address
Xiomara Triana
Filing Basis
1. intent to use
2. intent to use current
Disclaimer
"ONCE-DAILY" AND "OZANIMOD"
"ONCE-DAILY" AND "OZANIMOD" ONCE DAILY Pharmaceutical preparations for use in the treatment of leukemia, auto inflammatory disease, autoimmune disease, blood disease, cancer, multiple sclerosis, ulcerative colitis, arthritis, musculoskeletal and skin diseases; pharmaceutical preparations, namely, cytokine inhibitory drugs; pharmaceutical preparations that modulate the immune system; all of the fRead More
Pharmaceutical preparations for use in the treatment of leukemia, auto inflammatory disease, autoimmune disease, blood disease, cancer, multiple sclerosis, ulcerative colitis, arthritis, musculoskeletal and skin diseases; pharmaceutical preparations, namely, cytokine inhibitory drugs; pharmaceutical preparations that modulate the immune system; all of the foregoing being immunomodulators
No 97060574
No Service/Collective Mark
No 00160427-US
No
No
No
No
No
No
No
No
26.05.09 -
Triangles made of geometric figures, objects, humans, plants or animals
26.05.13 -
Two Triangles
26.05.21 -
Triangles that are completely or partially shaded
26.05.28 -
Miscellaneous designs with overall triangular shape
The mark consists of the term "ZEPOSIA" with a two stylized joined quadrilateral and triangle designs to the left with the term "once-daily" above the letters "ZE" and the wording "(OZANIMOD)" below it.
Status Date | Action Taken |
---|---|
02th Jan 2024 | NOA E-MAILED - SOU REQUIRED FROM APPLICANT |
07th Nov 2023 | PUBLISHED FOR OPPOSITION |
07th Nov 2023 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
18th Oct 2023 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
05th Oct 2023 | APPROVED FOR PUB - PRINCIPAL REGISTER |
04th Oct 2023 | TEAS/EMAIL CORRESPONDENCE ENTERED |
03rd Oct 2023 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
03rd Oct 2023 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
08th Jul 2023 | NON-FINAL ACTION WRITTEN |
08th Jul 2023 | NON-FINAL ACTION E-MAILED |